April 10, 2021
Business News

Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab


BURLINGAME, Calif.–()–Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab, today announced a strategic collaboration with Thermo Fisher Scientific, a world leader in serving science, to expand the manufacturing capacity for lenzilumab, currently in a Phase 3 registration study in patients with COVID-19, to support a potential Emergency Use Authorization (EUA).

This multi-year manufacturing partnership adds to Humanigen’s large scale commercial production efforts, including recently announced partnerships with Lonza and Catalent, in advance…



Click here to view the original article.

Related Posts

You might also like ...

Article feature image
Is Now The Time To Buy Stock In American Airlines, Carnival, Tesla Or GE?
Article feature image
Hawaii governor lays foundation for vaccinated travelers to avoid quarantine – The Points Guy
Article feature image
AstraZeneca Vaccine and Blood Clots: What Is Known So Far – The New York Times